Jennison Associates’s Arbutus Biopharma ABUS Stock Holding History

Jennison Associates’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-339,639	Closed	-$618K	–	621
2020 Q2	$618K	Sell	339,639 -15,127	-4%	-$24.8K	﹤0.01%	574
2020 Q1	$358K	Sell	354,766 -2,589,023	-88%	-$7M	﹤0.01%	605
2019 Q4	$8.18M	Buy	2,943,789 +2,178,665	+285%	+$3.53M	0.01%	397
2019 Q3	$1.17M	Buy	765,124 +137,125	+22%	+$236K	﹤0.01%	529
2019 Q2	$1.31M	Buy	+627,999	New	+$1.61M	﹤0.01%	527
2018 Q4	–	Sell	-269,699	Closed	-$2.55M	–	641
2018 Q3	$2.55M	Buy	+269,699	New	+$2.68M	﹤0.01%	511
2017 Q2	–	Sell	-140,019	Closed	-$455K	–	638
2017 Q1	$455K	Hold	140,019	–	–	﹤0.01%	610
2016 Q4	$343K	Buy	+140,019	New	+$407K	﹤0.01%	721

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates's ABUS Position: Q3 2020 in Review

Jennison Associates sold out of Arbutus Biopharma (ABUS) in Q3 2020, closing a stake of 339,639 shares — an estimated $618K sold.

Jennison Associates first reported a position in ABUS in Q4 2016 and held it in 8 quarters. The position peaked at $8.18M in Q4 2019. 65 funds tracked by Wall St. Rank hold ABUS as of Q3 2020.

Jennison Associates reported no remaining Arbutus Biopharma position as of Q3 2020 after selling out during the quarter.
Jennison Associates sold 339,639 Arbutus Biopharma shares in Q3 2020, an estimated $618K.
Jennison Associates first reported a position in Arbutus Biopharma in Q4 2016 and held it in 8 quarters.
Jennison Associates's Arbutus Biopharma position peaked at $8.18M in Q4 2019.
65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2020.

Based on Jennison Associates's 13F filing for Q3 2020, filed 4 Nov 2020.